This is an automatically translated article.
Phanabu 750 belongs to the group of pain relievers, antipyretics, non-steroidal anti-inflammatory drugs. Nabumetone is the main ingredient in this medication, which is commonly used to treat osteoarthritis, rheumatoid arthritis, and other conditions that require anti-inflammatory therapy.
1. What is Phanabu?
Phanabu 750 has the main ingredient Nabumetone - a non-steroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory effects. In particular, Nabumetone is also a non-narcotic analgesic, effective in relieving mild and moderate pain such as pain caused by trauma, menstrual pain, arthritis and other musculoskeletal conditions. Phanabu is often indicated for pain relief, anti-inflammatory in cases of degeneration, rheumatoid arthritis and osteoarthritis.Contraindications of Phanabu include:
Patients with hypersensitivity to Nabumetone or any component of Phanabu. Patients who are sensitive to aspirin or other NSAIDs such as asthma, nasal polyps, angioedema or urticaria. Patients with advanced peptic ulcer. Patients with liver failure, severe heart failure. Patients with severe renal impairment should not receive hemodialysis. Patients with a history of gastrointestinal perforation or bleeding related to previous NSAID therapy. Children under 15 years of age Pregnant and lactating women.
2. Dosage of Phanabu 75
Phanabu drug is usually taken orally, can be taken during or after meals. Patients should take the medicine at the same time of day. Depending on the subjects and treatment goals, the dose of Phanabu will be different, specifically as follows:
Adults: 500mg x 2 times/day orally before going to bed. If the disease is severe and prolonged, add 500-1000mg in the morning with a maximum dose of 1.5-2g/day. Elderly people: Use no more than 1g/day. Phanabu should not be given to children.
3. Side effects of Phanabu 750:
In some patients, using Phanabu may experience side effects such as:
Ulcers, gastrointestinal bleeding (common in the elderly), nausea, vomiting blood, diarrhea, flatulence , constipation, indigestion and black stools. Allergies: asthma, difficulty breathing, bronchospasm, itching, urticaria. Edema, high blood pressure, heart failure. High doses and prolonged use may lead to the risk of arterial thrombosis. Interstitial nephritis, nephritic syndrome and renal failure. Menorrhagia . Abnormal liver function, jaundice hepatitis. Ocular neuritis, headache, paresthesia, noninfectious meningitis with symptoms such as stiff neck, nausea, vomiting, headache, fever, disorientation, depression, hallucinations, dizziness, insomnia. Thrombocytopenia, neutropenia and hemolytic anemia. If you experience these symptoms, the patient should stop using Phanabu 750 and notify the doctor for appropriate treatment.
4. Precautions when using Phanabu 750:
Some general notes when using Phanabu include:
Be careful when using Phanabu in patients with liver failure, severe renal failure, history or current bronchial asthma. Do not use during the first 3 months of pregnancy and while breastfeeding. Caution should be exercised in patients with upper gastrointestinal disease or on anticoagulation therapy. The drug should be discontinued if signs of ulceration or gastrointestinal bleeding appear. Non-steroidal anti-inflammatory drugs may decrease renal prostaglandin synthesis in a dose-dependent manner leading to decreased renal perfusion. Administration of Phanabu in patients with severe hepatic impairment may increase serum transaminases or other indices of liver function. Combination therapy with anti-inflammatory drugs and analgesics only treats the symptoms, not the cause. Phanabu should be used with caution in patients with congestive heart failure and high blood pressure because it causes fluid retention and edema. Consider carefully before using Nabumetone to treat patients with ischemic heart disease, coronary artery disease or cerebrovascular disease.
5. Drug interactions with Phanabu 750:
The use of 2 or more non-steroidal anti-inflammatory drugs (including aspirin) should be avoided as the risk of undesirable effects may be increased. Nabumeton may reduce the therapeutic effect of antihypertensive drugs. Nabumeton increases the risk of nephrotoxicity when used with diuretics. Phanabu may worsen heart failure, decrease glomerular filtration rate and increase plasma glycoside concentrations when used in combination with cardiac glycosides. Nabumetone should not be used in patients with a history of asthma, rash, or allergies. Nabumetone reduces the elimination of lithium and methotrexate. Nabumeton increases the nephrotoxicity of Cyclosporin. Co-administration of Nabumeton with aluminum-containing antacids did not affect the bioavailability of 6MNA. Nabumetone is not addictive, stop taking Nabumetone at least 2 days before elective surgery. To avoid interactions, before being prescribed Phanabu 750, the patient should inform the doctor about the drugs they are using, including functional foods. The doctor will base it on that to prescribe the appropriate Phanabu 750.
Above is all information about Phanabu 750, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Note, Phanabu 750 is a prescription drug, patients absolutely must not buy drugs to treat at home because they may encounter unwanted side effects.
